Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration-resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
Clinical case reports. 2018 Jan 11*** epublish ***
Kota Shimokihara, Takashi Kawahara, Taisei Suzuki, Taku Mochizuki, Daiji Takamoto, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Masahiro Yao, Hiroji Uemura
Departments of Urology and Renal TransplantationYokohama City University Medical CenterYokohamaJapan., Department of HematologyYokohama City University Medical CenterYokohamaJapan., Department of UrologyYokohama City University Graduate School of MedicineYokohamaJapan.